Crinetics Pharmaceuticals (NASDAQ:CRNX) just reported results for the second quarter of 2024.
- Crinetics Pharmaceuticals reported earnings per share of -94 cents. This was below the analyst estimate for EPS of -86 cents.
- The company reported revenue of $399,000.
- This was 13.26% worse than the analyst estimate for revenue of $460,000.